CareDx, Inc. (CDNA) research
CareDx, Inc.- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Last price
- $54.33
- As of
CareDx, Inc. (CDNA): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-07-30.
As of . Source: SEC EDGAR filings for CDNA. Method and limitations.
Share the CDNA intelligence card
See CDNA live in the terminal
Track CDNA's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live CDNA terminal, freeActive signals for CDNA
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 93% of CDNA (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 51% of CDNA (2026Q2)
- highINSTITUTIONAL_SURGE
TWO SIGMA INVESTMENTS, LP added +74% to CDNA (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 51% of CDNA (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 93% of CDNA (2026Q2)
FREE, NO ACCOUNT
Every signal on CDNA, as it fires
You are seeing 5 of 16 signals recorded on CDNA since 2026-05-26.
The five above all landed on 2026-09-06. The other 11 were recorded on 4 other days. 11 of the 16 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in CDNA (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 14167L103 · 2026Q2 | $35.4M | 0.05% | , |
| D. E. Shaw & Co., Inc.CUSIP 14167L103 · 2026Q2 | $32.4M | 0.02% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 14167L103 · 2026Q2 | $11.5M | 0.01% | , |
| CITADEL ADVISORS LLCCUSIP 14167L103 · 2026Q2 | $3M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 14167L103 · 2026Q2 | $2.1M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, CDNA
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
CDNA against its peers
CDNA's operating margin of -8.1% ranks in the 66th percentile of 18 Diagnostics & Research sub-industry peers, fiscal periods ending between 2025-06-30 and 2025-12-31.
| Metric | CDNA | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 380M USD | 77.2M USD | 78 | 19 |
| Gross margin | n/a | 62.3% | n/a | 13 |
| Operating margin | -8.1% | -17.6% | 66 | 18 |
| Net margin | -5.6% | -20.6% | 63 | 19 |
| Return on equity | -7.0% | -6.4% | 50 | 16 |
Peers (21): NEO, PSNL, BLLN, OPK, QGEN, TWST, ICLR, BDSX, IMDX, BNR, FONR, QUCY, MDXH, PRPO, IDXG, LDDD, AWHL, MBAI, NDRA, XWEL, ISPC. Left out: ANPCF (no annual filing), PMDI (period gap), ADVB (no annual filing), BIAF (no annual filing). Fiscal periods ending between 2025-06-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (CDNA: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more CDNA signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to CDNAand get the insider, 13F, options, and confluence read in one view.